The incidence of Melanoma is rapidly growthing,and in China,dacarbazine combined with cisplatin is conmendly used as the first-line chemotherapy of metastatic melanoma. But the response rate and survival results are very limited.This trial aim to add a safe and effective anti-angiogenesis drug,Human-recombinant endostatin,to find out a new strategy which may further extend the PFS and OS with a tolerated toxicity.

Inclusion Criteria:

• 1. Histologically confirmed melanoma with metastases and has no received any systemic treatment.
• 2.At least one measurable site (diameter≥1cm) of disease (RECIST 1.1).
• 3.Estimated life expectancy of 12 weeks or greater
• 4. ECOG performance status 0, 1
• 5.Adequate organ function
• 6.Without symptoms of brain metastases and stable in neuro-functions

Exclusion Criteria:

• 1. Pregnant or lactation women
• 2. Acute infections without control.
• 3. Heart disease history, cardiac function class≥NYHA II.
• 4. HIV positive or chronic HBV/HCV in active stage.
• 5. Brain metastases or primary tumor with positive symptoms
• 6. Need anti-epileptic treatments
• 7. Organ transplantation history
• 8. Hemorrhagic tendency or related history
• 9. Renal dialysis patients
• 10. Diagnosis of any second malignancy within the last 3 years, except for adequately treated.
• 11. Current treatment on another clinical trial
• 12. The other improper situations which investigator judged.